Combination of irreversible electroporation and sting agonist for effective cancer immunotherapy

Eun Jin Go, Hannah Yang, Hong Jae Chon, Dasom Yang, Wonhyoung Ryu, Dong Hyun Kim, Dong Keun Han*, Chan Kim, Wooram Park

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Recently, cancer immunotherapy has received attention as a viable solution for the treatment of refractory tumors. However, it still has clinical limitations in its treatment efficacy due to inter-patient tumor heterogeneity and immunosuppressive tumor microenvironment (TME). In this study, we demonstrated the triggering of anti-cancer immune responses by a combination of irreversible electroporation (IRE) and a stimulator of interferon genes (STING) agonist. Optimal electrical conditions inducing damage-associated molecular patterns (DAMPs) by immunogenic cell death (ICD) were determined through in vitro 2D and 3D cell experiments. In the in vivo syngeneic lung cancer model, the combination of IRE and STING agonists demonstrated significant tumor growth inhibition. We believe that the combination strategy of IRE and STING agonists has potential for effective cancer immunotherapy.

Original languageEnglish (US)
Article number3123
Pages (from-to)1-15
Number of pages15
JournalCancers
Volume12
Issue number11
DOIs
StatePublished - Nov 2020

Keywords

  • Cancer immunotherapy
  • Combinational treatment
  • Immunogenic cell death (ICD)
  • Irreversible electroporation (IRE)
  • Stimulator of IFN genes (STING) agonists

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Combination of irreversible electroporation and sting agonist for effective cancer immunotherapy'. Together they form a unique fingerprint.

Cite this